Figure 5:

Treatment with tofacitinib prevents CD8 T cells from inducing pathology in Leishmania infection. RAG^−/− mice were infected with Leishmania and reconstituted with CD8 T cells. Two weeks post-infection, mice were treated with tofacitinib or vehicle for 2 weeks. (a) Ear thickness was measured weekly and at 4 weeks (b) parasite numbers was assessed. (c and d) neutrophil recruitment and (e and f) granzyme B expression by CD8 T cells was assessed directly ex vivo by flow cytometry at 4 weeks post-infection. (c and e) Representative contour plots and (d and f) bar graphs are representative of 2 individual experiments with 5 mice per group. Gating strategy: live, singlets, CD11b, Ly6G or CD3, CD8β. (g and h) Mice were infected with Leishmania in the skin and 2 weeks post-infection a subset of mice were co-infected with LCMV. 10 days post-LCMV infection mice were treated with tofacitinib or vehicle. (g) Ear thickness was measured weekly and at 6 weeks (h) parasite numbers was assessed. *p ≤ 0.05 and **p ≤ 0.01